Norepine (Noradrenaline Tartrate)

Norepinephrine tartrate stimulates α1‑adrenergic receptors, causing peripheral blood‑vessel constriction, and β1‑adrenergic receptors, enhancing heart‑muscle contractility and rate. The combined effect raises systemic vascular resistance and cardiac output, leading to a prompt increase in arterial pressure during shock states.

The dose of Norepine is individualized and set by the treating physician based on the patient’s hemodynamic status, response to therapy, and clinical condition. Dosing is typically titrated intravenously to achieve target blood‑pressure goals while monitoring for adverse effects.

Safety data for norepinephrine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and under specialist guidance.

To order Norepine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Norepinephrine is often preferred over dopamine because it provides stronger α‑adrenergic vasoconstriction with less tachyarrhythmia risk. Compared with phenylephrine, it also offers β1‑mediated cardiac support, making it suitable for patients who need both blood‑pressure elevation and modest inotropic effect.

Norepine should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect for particulate matter or discoloration and follow aseptic techniques for preparation and intravenous administration.

Norepine is given as an intravenous infusion, usually via a central line or a well‑secured peripheral catheter. The infusion rate is titrated by the clinician to achieve the desired blood‑pressure response, with continuous hemodynamic monitoring throughout the treatment.

Serious risks include severe hypertension, life‑threatening cardiac arrhythmias, and peripheral ischemia that can lead to tissue necrosis. Prompt recognition of excessive blood‑pressure rise, abnormal heart rhythms, or signs of compromised limb perfusion is essential for patient safety.

Norepine is contraindicated in patients with known hypersensitivity to norepinephrine or its excipients, and it should be used with extreme caution in individuals with uncontrolled hypertension, pheochromocytoma, or severe peripheral vascular disease where further vasoconstriction could be harmful.